AUS
NZ
UK
CA
USA
IND
Faron Pharmaceuticals Limited, operating in the healthcare sector, announced the appointment of Dr. Petri Bono as its new Chief Medical Officer (CMO), effective 15 August.
Faron Pharmaceuticals Limited revealed that Dr. Bono, formerly the CMO at Terveystalo, Finland's largest private healthcare service provider, and a previous leader at Helsinki University Hospital, will join the company later this month. Dr. Bono brings extensive experience in oncology and immunology to the role, having contributed significantly to numerous oncology trials from Phase 1 to Phase 3.
The announcement of Dr. Bono’s appointment was well-received, with the London-listed share price rising nearly 6% to 158.91p in Tuesday's trading. Dr. Bono has published over 100 peer-reviewed papers, with his research focusing on molecular and immunological oncology, making him an excellent fit for Faron (LSE:FARN)'s immuno-oncology programs.
Dr. Bono expressed enthusiasm for his new role, stating, "I am eager to further develop Faron's novel and innovative immunotherapy program, and to make bexmarilimab a cornerstone of future cancer care." He emphasized the potential of bexmarilimab, describing it as an exceptional asset with wide applicability in treating various cancers. "Bexmarilimab is an industry-leading agent in macrophage reprogramming and has shown it can induce responses and overcome treatment resistance in tumors," he added.
Faron's Chief Executive, Dr. Markku Jalkanen, commented on the appointment, "We are delighted to have such an experienced and proactive oncologist join us as the new CMO. This strengthens our upcoming expansion plans into solid tumors, as we benefit from Dr. Bono's expertise and broader strategic capabilities in both solid tumors and hematological malignancies."
Dr. Birge Berns, the company’s acting CMO seconded from tranScrip, will continue her role in developing bexmarilimab. She is expected to play a crucial part in Faron's ongoing discussions with the FDA and in shaping the company’s development and regulatory strategies.
The addition of Dr. Bono to Faron's leadership team marks a significant step in the company's mission to advance its immuno-oncology programs. With his extensive background in oncology and immunology, Dr. Bono is poised to drive the development of innovative therapies and expand Faron's presence in the oncology sector. The market's positive reaction reflects confidence in Faron's strategic direction and the potential impact of Dr. Bono's contributions.
